Rabbit Polyclonal CYP2D6 antibody. C-terminal. Suitable for WB, IHC-P and reacts with Human, Mouse, Rat samples. Immunogen corresponding to Synthetic Peptide within Human CYP2D6 conjugated to Keyhole Limpet Haemocyanin.
pH: 7.3
Preservative: 0.01% Sodium azide
Constituents: PBS, 30% Glycerol (glycerin, glycerine)
WB | IHC-P | |
---|---|---|
Human | Tested | Tested |
Mouse | Tested | Expected |
Rat | Tested | Expected |
Monkey | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500.00000 - 1/1000.00000 | Notes - |
Species Mouse | Dilution info 1/500.00000 - 1/1000.00000 | Notes - |
Species Rat | Dilution info 1/500.00000 - 1/1000.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Monkey | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Monkey | Dilution info - | Notes - |
Select an associated product type
A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:19965576, PubMed:20972997). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:18698000, PubMed:21289075). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Catalyzes the oxidative transformations of all-trans retinol to all-trans retinal, a precursor for the active form all-trans-retinoic acid (PubMed:10681376). Also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
CYP2DL1, CYP2D6, Cytochrome P450 2D6, CYPIID6, Cholesterol 25-hydroxylase, Cytochrome P450-DB1, Debrisoquine 4-hydroxylase
Rabbit Polyclonal CYP2D6 antibody. C-terminal. Suitable for WB, IHC-P and reacts with Human, Mouse, Rat samples. Immunogen corresponding to Synthetic Peptide within Human CYP2D6 conjugated to Keyhole Limpet Haemocyanin.
pH: 7.3
Preservative: 0.01% Sodium azide
Constituents: PBS, 30% Glycerol (glycerin, glycerine)
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
CYP2D6 also known as cytochrome P450 2D6 is a critical enzyme in the cytochrome P450 superfamily. It possesses a molecular mass of approximately 55 kDa. CYP2D6 is primarily expressed in the liver and to a lesser extent in the brain. As a monooxygenase it catalyzes the oxidation of organic substances including the metabolism of many xenobiotics and drugs. Its activity varies greatly among individuals due to genetic polymorphisms making it an important target for pharmacogenomic studies.
Enzymes related to drug metabolism perform essential roles in the detoxification of foreign chemicals. CYP2D6 is notably part of the microsomal enzyme complex in the liver. It facilitates the transformation of lipophilic compounds into more water-soluble metabolites rendering them easier for the body to excrete. This enzyme affects the bioavailability and efficacy of many medications such as antidepressants antipsychotics and beta-blockers. Its role is integral in the activation of certain prodrugs converting them into their active pharmacological forms.
CYP2D6 functions significantly in drug metabolism and clearance pathways. It takes part in the Phase I metabolism pathway where it initiates the oxidation of drugs setting the stage for further modifications. It interacts closely with other CYP enzymes like CYP3A4 which sometimes share substrates and inhibitors affecting their metabolic activities. CYP2D6's interaction with these pathways emphasizes its involvement in the intricate network of enzyme-mediated drug handling in the body.
Alterations in CYP2D6 activity relate to variations in drug metabolism leading to treatment challenges. For instance poor metabolizers may have increased risks of side effects or therapeutic failures in drugs like codeine which relies on CYP2D6 for activation. Additionally abnormal CYP2D6 activity associates with certain psychiatric disorders where specific drugs require precise metabolic conversion. The interaction between CYP2D6 and other proteins such as CYP3A4 further complicates its role in pharmacotherapy and its impact on individual responses to drugs.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-CYP2D6 antibody - C-terminal (ab230472) at 1/500 dilution
Lane 1: MCF7 (human breast adenocarcinoma cell line) whole cell lysate
Lane 2: NIH/3T3 (mouse embryo fibroblast cell line) whole cell lysate
Lane 3: H9C2 whole cell lysate
Predicted band size: 56 kDa
Formalin-fixed, parrafin-embedded human liver tissue stained for CYP2D6 antibody - C-terminal using ab230472 at 1/100 dilution in immunohistochemical analysis.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com